

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Brain cancer	K(lysine) acetyltransferase 2B (KAT2B; PCAF)	<p>Cell culture and mouse studies suggest inhibiting PCAF could help treat brain cancer by reducing sonic hedgehog homolog (SHH) signaling. A small interfering RNA screen of histone acetyltransferases found that knockdown of PCAF impeded SHH pathway activation. In glioblastoma and medulloblastoma cell lines, knockdown of PCAF decreased growth compared with no knockdown. In mice, intracranial injection of neural stem cells with PCAF knockdown led to lower tumor growth than injection of cells with no knockdown. Next steps include seeking collaborators to develop PCAF inhibitors.</p> <p><b>SciBX 6(37); doi:10.1038/scibx.2013.1019</b>  <b>Published online Sept. 26, 2013</b></p>	Unpatented; licensing status not applicable	<p>Malatesta, M. <i>et al. Cancer Res.</i>; published online Aug. 13, 2013; doi:10.1158/0008-5472.CAN-12-4660  <b>Contact:</b> Kristian Helin, University of Copenhagen, Copenhagen, Denmark                      e-mail: <a href="mailto:kristian.helin@bric.ku.dk">kristian.helin@bric.ku.dk</a></p>